We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Technologies and PREMIER Biosoft Couple Hardware-Software Platforms to Advance Glycomics Research
Product News

Agilent Technologies and PREMIER Biosoft Couple Hardware-Software Platforms to Advance Glycomics Research

Agilent Technologies and PREMIER Biosoft Couple Hardware-Software Platforms to Advance Glycomics Research
Product News

Agilent Technologies and PREMIER Biosoft Couple Hardware-Software Platforms to Advance Glycomics Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Agilent Technologies and PREMIER Biosoft Couple Hardware-Software Platforms to Advance Glycomics Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies, Inc. and PREMIER Biosoft have announced that a selection of Agilent’s high-resolution mass spectrometry and liquid chromatography instruments now support PREMIER Biosoft’s SimGlycan software. The combined analytical strength of Agilent instrumentation and PREMIER Biosoft’s glycan and glycopeptide data analysis software will open up a new level of discovery for researchers studying the biology of disease.

Glycomics is the study of glycome structures (sugars, modified sugars and saccharides) in molecules and organisms, a tangled web of carbohydrates, proteins and lipids that modulate cellular function and play a primary role in the development of cancer, bacterial and viral diseases, and glycan-specific hereditary diseases. These structures are very difficult to study due to their complexity and kinetics.

“Agilent and PREMIER Biosoft are focused on solving the glycan and glycopeptide identification problem in biopharmaceutical analyses,” said PREMIER Biosoft CEO Arun Apte. “Combining our powerful instruments and software will enable researchers to generate, process and analyze highly complex data so they can put it to use in drug development.”

“Used together, our powerful instrumentation and software fulfills a major unmet need for customers in biopharmaceutical research and development laboratories,” said David Edwards, Agilent’s senior director of LC/MS marketing.

Advertisement